Mannose-binding lectin (MBL) is a key element of the innate immunity, with a structure similar to complement C1q. Serum MBL levels are greatly affected by the polymorphisms of the MBL gene. In particular, codon 54 mutation of the MBL gene results in a significant reduction of serum MBL. To determine whether polymorphism of the MBL gene is associated with occurrence of systemic lupus erythematosus (SLE), rheumatoid arthritis and Sjö gren's syndrome in the Japanese population, we analyzed the MBL gene polymophisms of these patients and controls, by polymerase chain reactionrestriction fragment length polymorphism methods. We found that patients studied had a significantly higher frequency of having homozygous codon 54 mutation compared to controls. In particular, patients with SLE or Sjö gren's syndrome showed higher probabilities of being homozygous for this mutation. Among subjects with the same genotype, SLE patients tended to have higher serum MBL concentration than controls. Analysis of the promotor region suggested that SLE patients heterozygous for the codon 54 mutation have a higher probability of having a low producing haplotype for the gene without the codon 54 mutation. We conclude that persons homozygous for codon 54 mutation of the MBL gene may be prone to occurrence of autoimmune disorders including SLE, in the Japanese. MBL may have protective effects on occurrence and progression of SLE. Genes and Immunity (2001) 2, 99-104.
Introduction
Mannose-binding lectin (MBL) is a serum protein, which plays an important role in host defense against microorganisms.
MBL forms a trimer by three identical polypeptides. Several trimers further combine to form a bouquet-like structure resembling C1q of the complement pathway. 1 Each MBL polypeptide consists of a cysteine-rich region, carbohydrate recognition domain and a collagenous domain. While the carbohydrate recognition domain bind carbohydrates on various microorganisms, the collagenous domain of MBL may bind to collectin receptors on phagocytes. Thus, MBL helps phagocytosis of microorganisms by phagocytes. MBL also mediates lectin dependent activation of the complement pathway. 1 The importance of MBL in host defense is shown by the observation that people lacking this protein may have severe episodes of bacterial infection from early life. MBL deficiency occur as a result of polymorphisms in the MBL gene. The MBL gene is located on the long arm of chromosome 10 at 10q11.2-q21 and contains 4 exons. 2 Exon 1 codes for the cysteine-rich region and a part of the collagenous domain. Exon 2 codes for the remainder of the collagenous domain. Exons 3 and 4 code for the carbohydrate recognition domain. Several polymorphisms have been reported for the MBL gene. Codon 52, 54, 57 polymorphisms are all on exon 1, in a region coding for the collagenous domain of the MBL protein. Presence of any of the minority allele result in significant reduction of the serum MBL concentration, [3] [4] [5] [6] and are suggested to be associated with recurrent infections and progression of chronic viral diseases, such as acquired immunodeficiency syndrome, 7, 8 type B hepatitis 9 and type C hepatitis. 10 Polymorphisms in the promoter region of the MBL gene are also known to play a significant role in determining the serum MBL levels. Two such polymorphisms are the H/L polymorphism at −550 and the X/Y polymorphism at −221 of the MBL gene, reported by Madsen et al.
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The structure and the biological properties of MBL resemble those of C1q, and it is known that patients with C1q deficiency have a high probability of developing severe symptoms of systemic lupus erythematosus (SLE). [12] [13] [14] [15] [16] [17] Therefore, the association between occurrence of SLE and abnormality of MBL has drawn considerable attention. [18] [19] [20] [21] [22] [23] Senaldi et al 19 reported that patients with SLE have a higher frequency of having low levels of serum MBL than controls, 19 and others report on the MBL gene polymorphisms and occurrence of SLE, but the conclusions are not consistent among reports. In addition, a recent report showed that the absence of MBL protein increases the prevalence of RA, 24 while another study reported the absence of significant relationship between MBL gene polymorphisms and Sjö gren's syndrome (SJS). 25 To date, relationship between MBL polymorphism and SLE or other autoimmune disorders has not been firmly established.
In this study, we first investigated the frequency of four MBL alleles in Japanese subjects, and compared the occurrence of these alleles in SLE, rheumatoid arthritis (RA) and SJS. Results imply that homozygous mutation of the MBL gene may be associated with increased risk of having autoimmune disorders, especially SLE and SJS. Further analysis of the promotor region of the MBL gene suggest that individuals with absent or extremely low serum MBL concentration are prone to occurrence of autoimmune disorders.
Results
Codon 52 and 57 mutations of the MBL gene are absent or extremely rare in the Japanese Among 129 healthy Japanese volunteers, 39 were heterozygous and two were homozygous for the Codon 54 mutation (allele B) ( Table 1 ). Allele frequencies were 83.3% for the wild-type (allele A) and 16.7% for allele B. No individual with codon 52 or 57 mutation (alleles C or D) was found in our study population consisting of 129 healthy individuals and 266 patients with autoimmune disorders.
Individuals with homozygous codon 54 mutation of the MBL gene are significantly increased in patients with autoimmune disorders Genotypes of the MBL gene were studied on patients with autoimmune disorders (Table 1 ). The frequency of allele B in the patient group was mildly increased without statistical significance (P = 0.0627 by 2 analysis). The frequency of allele B in SLE patients was also mildly increased but without statistical significance (P = 0.0926 by 2 analysis). Significant differences were noticed in the prevalence of individuals homozygous for allele B of the MBL gene (Table 2) . Among 266 patients with autoimmune disorders, 17 were homozygous for allele B, significantly increased than those in healthy controls (6.4% vs 1.6%, P = 0.0350 by 2 analysis). When the autoimmune disorder group was subcategorized to each disease groups, individuals homozygous for allele B were increased in SLE patients (6.4%, P = 0.0431 by 2 analysis) and in SJS patients (14.3%, P = 0.0479 by Fisher's exact test, Table  2 ). In patients with RA, patients homozygous for allele B were slightly increased, but statistical significance was not achieved.
Among individuals with the same genotype, serum MBL concentrations are increased in patients with SLE SLE patients and healthy controls were categorized according to their MBL genotype, and serum MBL levels were measured in all subjects with genotype BB, and randomly selected subjects with genotype AA or AB. Serum MBL concentration was significantly decreased in subjects heterozygous for allele B, and undetectable in subjects homozygous for allele B, confirming the accuracy of the RFLP analyses (Table 3 ). When subjects with the same genotypes were compared, SLE patients tended to have higher MBL concentration than healthy controls (P = 0.0306 for genotype AA, P = 0.2313 for genotype AB, by Mann-Whitney's U test).
Analysis of promotor regions of the MBL gene suggest that individuals with absent or extremely low serum MBL are at risk of having autoimmune disorders
Having found that B/B homozygous, but not A/B heterozygous subjects were increased in the autoimmune disease patient group, we anticipated that among A/B heterozygous subjects, polymorphisms in the promotor Thus, the RFLP analysis enabled us to determine the MBL gene haplotypes of the subjects. Serum MBL levels were closely associated with the MBL haplotypes of the subjects included in this study. Among subjects heterozygous for the A/B polymorphism, subjects with the LXA haplotype had almost undetectable serum MBL levels, similar to those of B/B homozygous subjects (Figure 1 ). In A/B subjects, subjects with LXA haplotype, tended to be increased in SLE (6/47) and RA (4/32) patients than controls (1/29), although without statistical significance ( Table 4 ). The frequencies of allele H were 48.0%, 48.4%, 40.1%, 47.5%, and of allele Y were 89.5%, 91.5%, 91.7%, 93.2% for SLE, RA, SJS and controls, respectively. No significant differences in allele frequencies were observed among disease groups and controls.
SLE patients with homozygous MBL gene mutation did not show apparent characteristics
Profiles of SLE patients homozygous for allele B of the MBL gene were studied from patients' records.
The 10 SLE patients homozygous for allele B consisted of nine females and one male. Mean age at onset of SLE was 21.4 ± 5.9 years. Symptoms of SLE including skin rash, arthritis, serositis, central nervous system involvement, thrombocytopenia did not significantly differ from SLE patients not homozygous for this mutation. Eight patients homozygous for allele B underwent renal biopsy, and four were classified as WHO class V. However, due to the small number of patients with this genotype, statistical analysis was not done. Laboratory data including white blood cells and lymphocytes, hemoglobin, C3, C4, CH50, anti-nuclear antibody, anti-DNA, RNP, Sm, SS-A and SS-B antibodies did not significantly differ from SLE patients not homozygous for this mutation.
Discussion
There is growing interest on the role of MBL in host defense against infection. MBL gene polymorphisms have been reported, and it has been shown that individuals with heterozygous mutation of the MBL gene have lower serum values of MBL protein, and that individuals with homozygous mutations have even lower or almost undetectable concentration of this protein. This has been attributed to increased degradation of the mutated protein, because these mutations, all on the collagenous domain of the MBL protein, renders the protein unable to form a stable secondary structure. 4, 5 In this study, we have also made a similar observation in both SLE patients and healthy controls.
In this study, we found that the frequency of individuals with homozygous codon 54 mutation (allele B) of the MBL gene was significantly increased in our Japanese patients with autoimmune disorders, compared to Japanese healthy volunteers without known autoimmune disorders. When patients with autoimmune disorders were subcategorized to disease groups, patients with SLE or SJS seemed to have higher frequencies of being homozygous for this mutation. In accord to our previous observation, 10 codon 52 and 57 mutations of the MBL gene seemed to be absent in the Japanese population.
Among previous reports, Lau et al 20 reported that codon 54 substitution is slightly more frequent in SLE patients than in normal Chinese population, although statistical significance was not reached. They also pointed out that the serum MBL concentration is lower in SLE patients than in controls.
Davies et al reported that codon 54 mutation of the MBL gene is associated with SLE in an UK population 18 and a Spanish population. 22 In their studies, they showed that the frequency of mutated codon 54 allele is increased in UK and Spanish population, although the frequency of homozygous codon 54 mutation was not significantly increased. In our study, the allele frequency of this mutation seemed to be slightly increased in patients with autoimmune disorders than in healthy controls, but statistical significance was not achieved. However, of great interest is that frequency of individuals homozygous for the mutation was significantly increased in patients with autoimmune disorders, in particular, SLE or SJS. Most individuals with heterozygous MBL gene mutations have significantly low but easily detectable serum concentration of MBL. On the other hand, in individuals with homozygous MBL gene mutations, serum MBL will be almost undetectable.
3-6 Therefore, we speculated that compared to near complete deficiency of MBL, relatively low serum MBL is not a significant risk factor for occurrence of autoimmune disorders, including SLE. In this context, we hypothesized that among A/B heterozygous subjects, subjects with the LXA haplotype, the lowest MBL producing haplotype, will be at risk of having autoimmune disorders. Although not statistically significant, we did obtain results supporting this hypothesis. Our results are in contrast with those of Horiuchi et al, 23 in which they found that MBL gene polymorphisms are not risk factors for SLE or RA in the Japanese. The reason for this discrepancy is unclear, but differences in the study population and size could have played some roles.
Interestingly, SLE patients tended to have higher serum MBL concentrations than controls when subjects with the same MBL genotype were compared. It is possible that serum MBL levels fluctuate with disease activity of SLE or doses of steroids, although we could not find a significant relationship between MBL genotypes and disease activity or complement levels in the current study. A study with a larger sample size and with respect to disease activity and medication is necessary to determine whether altered serum MBL levels affect the course of SLE or vice versa. Recently, Garred et al 26 reported that SLE patients with homozygous MBL mutation are prone to acquiring serious infections compared with patients not homozygous for the mutation. They also pointed out that individuals with homozygous MBL mutation are more frequent in SLE patients than in controls, and that homozygous MBL mutation may possibly be associated with increased risk of renal involvement. We could not find a clear association between serious infections and MBL genotypes, but considering the protective nature of MBL against infection, this association requires more attention and may be important in the clinical management of SLE patients.
We have also found that homozygous mutation of the MBL gene may be a risk factor for occurrence of SJS. A recent study showed that there was no significant differences in allele, haplotype and genotype frequencies of the MBL gene between SJS patients and controls. 25 Although we did observe a significant difference in the Japanese, our sample number is not large, and the confirmation of this association needs further studies in larger scales.
RA patients were also included in this study. Recently, Graudal et al 24 reported that patients with RA had a larger probability of lacking detectable serum levels of MBL. They suggested that MBL deficiency may be related to occurrence of RA, possibly by increased chances of infection by retroviruses or other pathogens. On the other hand, Malhotra et al 27 suggested that MBL may have a significant role in the pathogenesis of RA, through enhanced binding of MBL to IgG with altered glycosylation, which is markedly increased in patients with RA. If this is the case, one may expect that MBL deficiency may have protective effects against occurrence of RA. In our study, although not statistically significant, patients with RA did have a higher probability of being homozygous for the codon 54 mutation of the MBL gene. Subjects with LXA haplotype also seemed to be increased in RA patients with A/B genotype. Thus, similar to SLE, near nonexisting levels of serum MBL may be related to occurrence of RA. It would be of interest to investigate whether this relationship is valid and to study the characteristics of RA patients with MBL deficiency. In this respect, very recently Graudal et al 28 reported that RA patients with homozygous mutation of the MBL gene had significantly worse prognosis of the disease than patients not homozygous for the mutation. In their study, homozygosity for the MBL gene mutation was slightly increased than healthy controls (3.6% and 2.6% of RA patients and controls, respectively), without statistical significance. MBL deficiency may be a risk factor and also be a poor prognostic factor for RA patients, and this association may be important for the management of RA, when established by more studies.
In summary, we have shown that homozygous MBL gene codon 54 mutation may affect the risk factor of having autoimmune disorders, in particular, SLE and SJS. We have also obtained data suggesting that the low producing allele of the MBL gene may also be a risk factor of SLE in patients heterozygous for the codon 54 mutation. Accumulation of SLE, SJS and RA cases with MBL deficiency is necessary to determine whether there are symptoms or laboratory data characteristic for patients with the mutation, and establish the importance of MBL gene typing in clinical management of these patients.
Patients and methods

Patients and controls
Samples from 266 patients with autoimmune disorders, followed at Department of Medicine II, Hokkaido University Hospital, Japan, were used. Patients with SLE, RA and SJS were included in this study. All patients fulfilled the American College of Rheumatology Classification Criterias for their diseases, except for patients with primary SJS, who fulfilled the Japanese Ministry of Health criteria for the classification of SJS. Written informed consent was obtained from all participants of this study. 3 Genomic DNA from peripheral blood leukocytes were amplified by PCR, and the products were digested by the restriction enzymes shown above. Underlined mutations were generated to introduce a Hha I site in amplified products from alleles A, B and C, and a Mlu I site in products from alelle D. Samples can be typed to homozygotes or heterozygotes of these four alleles, by two reactions of PCR-RFLP. Numbers in parenthesis show positions of the primers on the MBL gene. MBL, mannose-binding lectin. Genomic DNA from peripheral blood leukocytes were amplified by PCR, and the products were digested by the restriction enzymes shown above. Underlined mutation was generated for HL reverse primer to introduce Acc I restriction site into allele L of the MBL gene.
Samples from 129 healthy Japanese served as controls. For the promoter region analyses, only samples from 252 autoimmune disease patients and 81 healthy volunteers were used, since some samples were no longer available for the analyses.
Typing of the MBL gene
Typing of the MBL gene alleles were done according to the methods of Madsen et al. 3 Here, the wild-type allele is designated allele A, and codon 54 substitution (glycine to aspartic acid), codon 57 substitution (glycine to glutamic acid) and codon 52 substitution (arginine to cysteine) were designated alleles B, C and D, respectively.
Genomic DNA was purified from peripheral blood leukocytes using DnaQuick DNA purification kit (Dainippon Pharmaceuticals, Osaka, Japan) following the manufacturer's recommended protocol. Two sets of PCR reactions were done using primers shown in Table 5 . Products were digested by appropriate restriction enzymes, and the alleles were typed according to the sizes of the digested products (Table 5 and Madsen et al   3   ) . Two polymorphisms at positions −221 (c: allele X, g: allele Y), and −550 (g: allele H, c: allele L) of the promotor region of the MBL gene were studied. Two sets of PCR reactions were done using primers shown in Table 6 . Products were digested by appropriate restriction enzymes, and the alleles were typed according to the sizes of the digested products (Table 6) .
Genes and Immunity
Measurement of the serum MBL concentration by enzyme immunoassay Serum concentration of MBL was measured by a specific enzyme immunoassay utilizing two rabbit polyclonal anti-MBL antibodies as described. 29 Briefly, microtiter plates were coated with 10 g/ml of rabbit anti-MBL overnight. After blocking procedures, samples were incubated for 1 h at 37°C. Bound MBL was detected with a biotin labeled anti-MBL antibody raised independently from the antibody used for the coating of assay plates. Standard curves were generated with recombinant MBL prepared as described. 29 
Statistical analyses
Chi-square analysis was used to compare the frequencies of alleles A and B, or genotypes AA/AB or BB, between disease and control groups. Fisher's exact test was used where appropriate. P values equal or less than 0.05 were considered as significant.
